NASDAQ:FENC Fennec Pharmaceuticals (FENC) Stock Price, News & Analysis $5.29 -0.08 (-1.49%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$5.07▼$5.3950-Day Range$5.29▼$6.7352-Week Range$5.00▼$11.92Volume93,743 shsAverage Volume119,791 shsMarket Capitalization$144.57 millionP/E Ratio176.33Dividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Fennec Pharmaceuticals alerts: Email Address Fennec Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside164.7% Upside$14.00 Price TargetShort InterestBearish8.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$37,169 Sold Last QuarterProj. Earnings Growth-11.11%From $0.27 to $0.24 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.77 out of 5 starsMedical Sector818th out of 910 stocksBiological Products, Except Diagnostic Industry142nd out of 155 stocks 3.5 Analyst's Opinion Consensus RatingFennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFennec Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Fennec Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.37% of the float of Fennec Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverFennec Pharmaceuticals has a short interest ratio ("days to cover") of 18.6, which indicates bearish sentiment.Change versus previous monthShort interest in Fennec Pharmaceuticals has recently decreased by 1.55%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldFennec Pharmaceuticals does not currently pay a dividend.Dividend GrowthFennec Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FENC. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Fennec Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for FENC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fennec Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $37,169.00 in company stock.Percentage Held by Insiders10.98% of the stock of Fennec Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.51% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fennec Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Fennec Pharmaceuticals are expected to decrease by -11.11% in the coming year, from $0.27 to $0.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fennec Pharmaceuticals is 176.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 127.87.Price to Earnings Ratio vs. SectorThe P/E ratio of Fennec Pharmaceuticals is 176.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 115.64.Read more about Fennec Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…Go here now to watch my new documentary About Fennec Pharmaceuticals Stock (NASDAQ:FENC)Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Read More FENC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FENC Stock News HeadlinesSeptember 5 at 6:56 AM | globenewswire.comFennec Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 30, 2024 | finance.yahoo.comFennec Pharmaceuticals Inc (RV41.BE)September 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 28, 2024 | americanbankingnews.comHC Wainwright Cuts Fennec Pharmaceuticals (NASDAQ:FENC) Price Target to $13.00August 28, 2024 | americanbankingnews.comFY2024 EPS Estimates for Fennec Pharmaceuticals Inc Decreased by Analyst (NASDAQ:FENC)August 28, 2024 | americanbankingnews.comHC Wainwright Trims Fennec Pharmaceuticals (NASDAQ:FENC) Target Price to $13.00August 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Fennec Pharmaceuticals Amidst PEDMARK’s Long-Term Growth PotentialAugust 21, 2024 | finance.yahoo.comFennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are Reducing Their Forecasts For This YearSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 15, 2024 | uk.finance.yahoo.comFennec Pharmaceuticals Second Quarter 2024 Earnings: Misses ExpectationsAugust 15, 2024 | markets.businessinsider.comBuy Rating for Fennec Pharmaceuticals Bolstered by Pedmark’s Market Expansion and New LeadershipAugust 15, 2024 | markets.businessinsider.comOptimistic Buy Rating for Fennec Pharmaceuticals Amidst Pedmark’s Market Expansion and Strong Financial OutlookAugust 14, 2024 | gurufocus.comQ2 2024 Fennec Pharmaceuticals Inc Earnings Call TranscriptAugust 14, 2024 | finance.yahoo.comQ2 2024 Fennec Pharmaceuticals Inc Earnings CallAugust 13, 2024 | globenewswire.comFennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 7, 2024 | markets.businessinsider.comBuy Rating Affirmed Amid Leadership Transition and Strong Growth Prospects for Fennec PharmaceuticalsAugust 7, 2024 | investing.comFennec Pharmaceuticals names new CEO to expand PEDMARK reachAugust 6, 2024 | globenewswire.comFennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024See More Headlines Receive FENC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FENC CUSIPN/A CIK1211583 Webwww.fennecpharma.com Phone919-636-4530Fax919-890-0490EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$15.00 Low Stock Price Target$13.00 Potential Upside/Downside+164.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.03 Trailing P/E Ratio176.33 Forward P/E Ratio19.59 P/E GrowthN/ANet Income$-16,050,000.00 Net Margins5.59% Pretax Margin5.58% Return on Equity-53.38% Return on Assets6.14% Debt Debt-to-Equity Ratio9.86 Current Ratio8.02 Quick Ratio7.75 Sales & Book Value Annual Sales$48.89 million Price / Sales2.96 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-105.80Miscellaneous Outstanding Shares27,328,000Free Float24,327,000Market Cap$144.57 million OptionableOptionable Beta0.29 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Rostislav Raykov (Age 42)Pres, CEO & Director Mr. Robert C. Andrade (Age 43)Chief Financial Officer Mr. Mark GowlandControllerMr. Lei FangPres of Pharstat IncMs. Anne McKay (Age 64)Regulatory Consultant Key CompetitorsREGENXBIONASDAQ:RGNXiTeos TherapeuticsNASDAQ:ITOSProKidneyNASDAQ:PROKAllogene TherapeuticsNASDAQ:ALLOValnevaNASDAQ:VALNView All CompetitorsInsiders & InstitutionsThe Manufacturers Life Insurance Company Bought 11,310 shares on 8/15/2024Ownership: 0.041%WINTON GROUP LtdBought 67,005 shares on 8/9/2024Ownership: 0.245%Acadian Asset Management LLCBought 8,086 shares on 8/6/2024Ownership: 0.030%Rosty RaykovSold 2,431 sharesTotal: $15,193.75 ($6.25/share)Rhumbline AdvisersBought 8,987 shares on 8/1/2024Ownership: 0.107%View All Insider TransactionsView All Institutional Transactions FENC Stock Analysis - Frequently Asked Questions How have FENC shares performed this year? Fennec Pharmaceuticals' stock was trading at $11.22 at the beginning of the year. Since then, FENC shares have decreased by 52.9% and is now trading at $5.29. View the best growth stocks for 2024 here. How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of $0.06 by $0.26. The business had revenue of $7.26 million for the quarter, compared to analysts' expectations of $13.67 million. Fennec Pharmaceuticals had a net margin of 5.59% and a negative trailing twelve-month return on equity of 53.38%. Who are Fennec Pharmaceuticals' major shareholders? Top institutional investors of Fennec Pharmaceuticals include Bank of New York Mellon Corp (0.25%), WINTON GROUP Ltd (0.25%), Rhumbline Advisers (0.11%) and The Manufacturers Life Insurance Company (0.04%). Insiders that own company stock include Rosty Raykov, Robert Andrade, Chris A Rallis and Adrian Haigh. View institutional ownership trends. How do I buy shares of Fennec Pharmaceuticals? Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD) and Trevena (TRVN). This page (NASDAQ:FENC) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fennec Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
